Tag - alzheimers

 
Menu
Search
 
May 04, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

ALZHEIMERS

Japan Times
BUSINESS / Markets
Jan 10, 2023
Eisai shares jump after FDA approves Alzheimer’s drug lecanemab
The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.
Japan Times
WORLD / Science & Health
Jan 7, 2023
Alzheimer’s drug made jointly by Japan's Eisai wins accelerated U.S. approval
The U.S. has called the drug 'an important advancement in the ongoing fight' against the debilitating disease. But its $26,000 price tag could put it out of reach for many.
Japan Times
BUSINESS / Companies
Dec 28, 2022
Tokyo firm targets blood tests for Alzheimer's in wake of therapy breakthrough
Fujirebio Holding is boosting its lineup of reagents used to detect Alzheimer's biomarkers in blood tests.
Japan Times
JAPAN / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer’s
Japan has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
Japan Times
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer’s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
COMMENTARY / World
Oct 4, 2022
New Alzheimer's drug from Biogen and Eisai is just the beginning
A successful late-stage trial of lecanemab gives researchers promising new avenues for tackling this hard-to-beat disease.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug's trial success raises hope for Alzheimer's prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Alzheimer’s progression slowed by drug in major trial
The drug slowed cognitive decline in people with early Alzheimer's by 27% over 18 months when compared with a placebo using a common rating scale.
Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer’s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan Times
WORLD / Science & Health
Apr 19, 2022
Scientists question data behind an experimental Alzheimer’s drug
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
Japan Times
BUSINESS
Apr 9, 2022
Japan's Eisai still seeking accelerated U.S. review of Alzheimer's drug
The firm said it plans to seek a quick approval even after the Medicare health plan decided to limit coverage of medicines approved in that manner.
Japan Times
COMMENTARY / World
Mar 17, 2022
The silver lining hidden in the battle against long COVID
Long COVID-19 research could reveal clues to help fight Alzheimer's, Lyme Disease and other illnesses.
Japan Times
WORLD / Science & Health
Jan 12, 2022
Biogen stung as U.S. limits coverage of Alzheimer’s therapy
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
Japan Times
JAPAN / Science & Health
Dec 24, 2021
Japan university finds Alzheimer's drug effective in treating ALS
There are drugs that can slow the progress of the disease, but the new medicine could be the first to work on protein accumulated in the brain and spinal cord.
Japan Times
WORLD
Sep 3, 2021
Lawmakers probe ‘anomalies’ in approval of Biogen Alzheimer’s drug
The congressional inquiry adds to pressure on the U.S. agency charged with regulating products that account for one-fifth of consumer spending.
Japan Times
WORLD / Science & Health
Jul 29, 2021
Doctors blast Biogen Alzheimer approval as ‘regulatory failure’
The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency's decision.
Japan Times
COMMENTARY / World
Jul 19, 2021
Latest U.S. Alzheimer's drug fix is a patch job
Most of the FDA's decisions don't receive national attention, which means they may not be rectified until substantial harm is done.
Japan Times
BUSINESS / Companies
Jul 13, 2021
Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first
The U.S. Food and Drug Administration's June approval of Aduhelm caused resignations among a panel of independent experts who said the therapy was ineffective.
Japan Times
COMMENTARY / World
Jun 14, 2021
Alzheimer’s drug furor highlights U.S. health system’s failures
The FDA didn't deny that the clinical-trial evidence was poor. It simply ignored that problem and used different reasoning to grant the drug 'accelerated approval.”
Biden calls ally Japan ‘xenophobic’ along with rivals China and Russia
U.S. President Joe Biden speaks in Syracuse, New York, on April 25.
Yen swings stir talk that Japan is in the FX market once again
An electronic screen in Tokyo displays the yen exchange rate against the U.S. dollar and the graph showing its recent swings, on Thursday.
Harajuku strives to reclaim its former glory — and surpass it
Laforet Harajuku, which celebrated its 45th anniversary last year, has been a witness to the district's evolution over the years.
Weak yen fattens tourist wallets in Japan
People visit the Ameya Yokocho market in Tokyo's Ueno district during the Golden Week holiday on Tuesday.
Japan's May 1 intervention may have cost ¥3.66 trillion, BOJ data suggests
An electronic screen displays a graph showing Japanese yen exchange rates surging against the dollar amid signs of intervention by authorities, in Tokyo on Thursday.
Kishida sets sights on energy and climate in South America trip
Prime Minister Fumio Kishida will use a policy speech in Sao Paulo to set out his vision for ties between Japan and South America, almost 10 years after former Prime Minister Shinzo Abe advocated for stronger ties between the two in the same city.
Yellow sand allergy: A health issue made worse by climate change
A screenshot of the Meteorological Agency's satellite image of clouds and yellow sand (in pink) on Sunday.
Climate change, chalky grains and the risks for Japan’s rice farmers
A farmer plants seedlings in Satsumasendai, Kagoshima Prefecture. Japan’s self sufficiency rate for rice is nearly 100%, compared with 38% for food overall, on a calorie basis.
Japan wants you to spend more with ‘luxury tourism’
Performers play a traditional drum unique to Wajima, Ishikawa Prefecture, in the prefectural capital of Kanazawa on March 16 to mark the extension of the Hokuriku Shinkansen line to Tsuruga Station in Fukui Prefecture.
Theaster Gates’ ambitious ‘Afro-Mingei’ brings Black Chicago to Tokyo
Theaster Gates' “A Heavenly Chord” lines up church pews before seven speakers and a Hammond B3 organ, a type of electric organ prevalent in Black American churches.

Podcast

From easily navigable train stations to the helpfulness of its municipal staff, Tokyo has earned high praise for its commitment to accessibility for disabled travelers.
[Rebroadcast] Japan is doing better on accessibility than you may think

Longform

Rows of irises resemble a rice field at the Peter Walker-designed Toyota Municipal Museum of Art.
The 'outsiders' creating some of Japan's greenest spaces
By Stephen Mansfield

SUSTAINABLE JAPAN

Vol. 35: Travel in time — and stay there
Vol. 35: Travel in time — and stay there

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER